Generics now dominate the semaglutide market worldwide, pushing brand‑name sales into a more limited niche. Industry trackers note that after a rapid rise in India, sales of generic weight‑loss drugs have tapered and overall demand has levelled off. Recent research finds the drug’s weight‑loss effect fluctuates widely between users, with some seeing strong results and others modest change. Novo Nordisk announced a partnership with Vivani to create a sustained‑release semaglutide implant that could release the drug over multiple months. The development aims to give the company a new option as generic competitors capture more of the market. Analysts say the implant could transform treatment patterns if clinical trials confirm its safety.